Pfizer to discontinue development programme for PF-07265803 for LMNA-related dilated cardiomyopathy EP News Bureau Aug 5, 2022 Decision follows results of interim futility analysis which indicate phase-III REALM-DCM trial unlikely to meet primary endpoint
